Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
BioAlliance Pharma
BioAlliance Pharma
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Overcoming CMC challenges in cell and gene therapy: part II
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC...
SNIPR Biome receives funding to progress CRISPR medicine SNIPR001 into clinical trials
Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation
Kindeva Drug Delivery appoints Denis Johnson as Chief Operating Officer
Denis will be responsible for optimising global operations for the company
SeaBeLife awarded over €1.5 million in i-Nov innovation competition
Funding for company’s SeaBeEYE project will be used to develop a new therapeutic approach for geographic atrophy, a form of age-related macular degeneration
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Finance
Shareholders approve merger of BioAlliance Pharma and Topotarget
The combined business will be renamed Onxeo after completion of the transaction
Research & Development
Merger of BioAlliance Pharma and Topotarget to create new company called Onxeo
Transaction is expected to be completed in July/August
Finance
BioAlliance Pharma to merge with Topotarget
The companies have a pipeline of orphan oncology drugs
Manufacturing
BioAlliance Pharma collaborates with Penn Pharma on development of Validive
BioAlliance Pharma entrusts the pharmaceutical development of Validive to Penn Pharma, including the production of phase III clinical batches and the commercial production
Pharmaceutical
BioAlliance Pharma makes appointment
Judith Greciet put in charge of operations and r&d as deputy chief operating officer
Research & Development
BioAlliance receives €2m for Lauriad research project
French firm will capitalise on its mucosal expertise
Research & Development
BioAlliance receives ANR funding
To develop new applications of its mucoadheasive Lauriad technology
Subscribe now